Kristin Sanford

Download

Biography

Kristin Sanford
Kristin Sanford is a partner in Weil’s Antitrust group. Her practice focuses on mergers and acquisitions, government investigations, and general antitrust counseling with experience across a wide range of industries, including medical devices, pharmaceuticals, hospitality, and retail, among others.

In 2024 and 2025, Lawdragon 500 named Kristin to its “X – The Next Generation” list.

Prior to joining Weil, Kristin interned at the US Federal Trade Commission in a commissioner’s office. Kristin is a member of the American Bar Association’s Section of Antitrust Law, served as a Young Lawyer Representative for the Section’s Task Force on International Divergence of Dominance Standards (2017 – 2019), and has been a contributing editor to the ABA’s Annual Review of Antitrust Law Developments.

Kristin obtained her J.D. from the Georgetown University Law Center where she served as a Law Fellow in the Legal Research and Writing Department. She earned her B.A., with distinction, from Duke University. Prior to law school, Kristin was a revenue management analyst at American Airlines.

Key Representations

  • Cedar Fair, L.P. in its merger with Six Flags Entertainment.
  • Johnson & Johnson in numerous transactions, including:
    • The acquisition of medical device maker V-Wave for up to $1.7 billion
    • The $13.1B acquisition of Shockwave Medical
    • The $275M+ sale of its Acclarent ENT surgery division to Integra
    • The ~$16.6 billion acquisition of heart pump maker Abiomed Inc.
    • The acquisition of orthopedic company CrossRoads Extremity Systems
    • The ~$1.045 billion divestiture of the Codman Neurosurgery business to Integra LifeSciences Holding Corporate
  • NanoString Technologies, Inc. in a patent and antitrust litigation against 10x Genomics, Inc. and Harvard College in the District of Delaware.
  • Abbott Laboratories in its $850 million acquisition of Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
  • C&S Wholesale Grocers in connection with the Federal Trade Commission’s study under Section 6(b) of the FTC Act regarding the competitive impact of supply chain disruptions in consumer goods.
  • Meta (f/k/a Facebook) in its acquisition of Kustomer, a customer relationship management company.
  • Fidelity National Financial, Inc. in New York Attorney General Letitia James’ investigation into possible violations of New York state antitrust laws and Section 1 of the Sherman Act. The investigation was part of the Attorney General’s broader review of alleged “no-poach” agreements between competitors in the title insurance industry.
  • A leading television broadcaster in an investigation by the U.S. Department of Justice alleging that broadcasters unlawfully shared revenue pacing information and negotiation of a consent decree to resolve and settle the DOJ Antitrust Division’s claims.
  • Maxim Integrated Products, Inc., a semiconductor manufacturer, in its over $20 billion sale to Analog Devices, Inc.
  • BASF in its $11B acquisition of seed and herbicide businesses and assets pursuant to a DOJ antitrust consent decree in connection with Bayer’s acquisition of Monsanto. At the time, BASF’s acquisition was the largest negotiated merger divestiture in the history of US antitrust enforcement.
  • Abbott Laboratories, a global, broad-based health care company, in its acquisition of Alere Inc., a global leader in point of care diagnostics, in a deal valued at approximately $5.3 billion, successfully securing clearance from the U.S. Federal Trade Commission.
  • The Sherwin-Williams Company in its $11.3 billion acquisition of The Valspar Corporation, a leading manufacturer of paint and coatings.
  • The Great Atlantic & Pacific Tea Company, Inc. (A&P) in its chapter 11 case. As part of the chapter 11 plan, A&P sought to sell 120 stores to supermarket competitors, including Albertsons, Royal Ahold, and Key Food Stores. Weil secured antitrust clearance from the FTC for the sale of A&P’s stores, relying in part on the rarely-successful failing firm defense.
  • Iron Mountain in its $2.6 billion acquisition of Recall Holdings, successfully securing regulatory approval from the U.S. Department of Justice.
  • AbbVie, a global biopharmaceutical company, in its acquisition of Pharmacyclics, Inc., a transaction valued at $21 billion and which closed without the FTC issuing a Second Request.

Awards and Recognition, Speaking Engagements, Latest Thinking, Firm News & Announcements

Awards and Recognition

Speaking Engagements

Latest Thinking

View all

Firm News & Announcements

View all